Indications/Uses
Hypokalemia. Prophylaxis during treatment with saluretic diuretics, especially in combination with digitalis.
Dosage/Direction for Use
Adults including the elderly: Prophylaxis: Individual dosage with a minimum dose of 2 tablets daily.
Hypokalemia: The dosage should be adjusted according to the serum potassium level. Suggested dosage: 2 tablets twice a day, or more, until serum potassium is restored to normal, then prophylactic dosage.
Impaired renal function: Patients with renal impairment may required lower doses. Monitoring of the serum electrolytes is required.
Children: There is limited experience with Potassium Chloride (Kalium Durules) in children.
The tablets should be swallowed whole, not broken or chewed, together with half a glass of liquid. The tablets should not be administered to a patient in a supine position.
Hypokalemia: The dosage should be adjusted according to the serum potassium level. Suggested dosage: 2 tablets twice a day, or more, until serum potassium is restored to normal, then prophylactic dosage.
Impaired renal function: Patients with renal impairment may required lower doses. Monitoring of the serum electrolytes is required.
Children: There is limited experience with Potassium Chloride (Kalium Durules) in children.
The tablets should be swallowed whole, not broken or chewed, together with half a glass of liquid. The tablets should not be administered to a patient in a supine position.
Overdosage
Symptoms: Mainly cardiovascular (hypotension, shock, ventricular arrhythmias, bundle-branch block, ventricular fibrillation leading possibly to cardiac arrest), neuromuscular and gastrointestinal. Beside elevation of serum potassium concentration, typical ECG changes are also noted (increasing amplitude and peaking of T waves, disappearance of P wave, widening of QRS complex and S-T depression).
Management: Gastric lavage, preferably with physiological saline. Continuous ECG-monitoring, close monitoring of electrolytes and blood gases. Infusion of physiological saline, correction of metabolic acidosis with intravenous sodium bicarbonate. Infusion of glucose and insulin, forced diuresis and possibly peritoneal dialysis or hemodialysis. Use of exchange resins. In case of cramps diazepam.
Management: Gastric lavage, preferably with physiological saline. Continuous ECG-monitoring, close monitoring of electrolytes and blood gases. Infusion of physiological saline, correction of metabolic acidosis with intravenous sodium bicarbonate. Infusion of glucose and insulin, forced diuresis and possibly peritoneal dialysis or hemodialysis. Use of exchange resins. In case of cramps diazepam.
Administration
Should be taken with food: Swallow whole w/ ½ glass of liqd, do not break/chew/crush. Do not administer to a patient in a supine position.
Contraindications
Renal insufficiency, hyperkalemia, untreated Addison's disease, stricture of the esophagus and/or obstructive changes in the alimentary tract. Hypersensitivity to the active substance or to any of the excipients.
Special Precautions
The product should be used with caution in the presence of obstructive changes in the alimentary tract, especially in patients with constriction of the esophagus, when there is a potential risk of esophageal complications (local irritation). A liquid potassium product is recommended as a substitute in these cases.
Monitoring of serum electrolytes is particularly necessary in patients with heart or kidney disease.
Effects on Ability to Drive and Use Machines: Potassium Chloride (Kalium Durules) has no or negligible influence on the ability to drive and use machines.
Monitoring of serum electrolytes is particularly necessary in patients with heart or kidney disease.
Effects on Ability to Drive and Use Machines: Potassium Chloride (Kalium Durules) has no or negligible influence on the ability to drive and use machines.
Use In Pregnancy & Lactation
Animal reproduction studies have not been conducted with Potassium Chloride (Kalium Durules). It is not known whether Potassium Chloride (Kalium Durules) can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. It is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity. Potassium Chloride (Kalium Durules) should be given to a pregnant woman only if clearly needed and under physician's guidance with periodic monitoring of serum level.
Drug Interactions
Concomitant administration of potassium salts and potassium-sparing diuretics like aldosterone antagonists (e.g. spironolactone), amiloride or triamterene may cause severe hyperkalemia and should be avoided.
Tacrolimus may cause hyperkalemia or increase the serum concentration of potassium which should be taken into account when combined with potassium salts.
ACE inhibitors may produce some increase in potassium serum levels by inhibiting aldosterone secretion. Potassium supplements should be given to patients concomitantly taking ACE inhibitors only with close monitoring of potassium levels.
Tacrolimus may cause hyperkalemia or increase the serum concentration of potassium which should be taken into account when combined with potassium salts.
ACE inhibitors may produce some increase in potassium serum levels by inhibiting aldosterone secretion. Potassium supplements should be given to patients concomitantly taking ACE inhibitors only with close monitoring of potassium levels.
Storage
Store at temperatures not exceeding 30°C.
Action
Pharmacology: Pharmacodynamics: Potassium plays a major role in a number of physiological processes like the maintenance of intracellular tonicity, the transmission of nerve impulses, the renal function and the contraction of cardiac, skeletal and smooth muscle.
Potassium depletion may occur when the loss through renal excretion and/or the loss from the gastrointestinal tract exceeds the potassium intake.
Pharmacokinetics: The bioavailability of potassium from Potassium Chloride (Kalium Durules) is similar to that of a standard potassium chloride solution. The Tmax for excretion occurs after 1-1.5 hours after intake of Potassium Chloride (Kalium Durules).
Potassium depletion may occur when the loss through renal excretion and/or the loss from the gastrointestinal tract exceeds the potassium intake.
Pharmacokinetics: The bioavailability of potassium from Potassium Chloride (Kalium Durules) is similar to that of a standard potassium chloride solution. The Tmax for excretion occurs after 1-1.5 hours after intake of Potassium Chloride (Kalium Durules).
MedsGo Class
Electrolytes
Features
Dosage
750 mg
Ingredients
- Potassium Chloride
Packaging
Sustained Release Tablet 100's
Generic Name
Potassium Chloride
Registration Number
DR-9941
Classification
Prescription Drug (RX)
Product Questions
Questions
